GlassScriptPhysician profile
Calvin Rosenfeld
NPI 1386600336
$5,930.37
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,486 · 2020: $1,463 · 2021: $1,284 · 2022: $123 · 2023: $550 · 2024: $23.96.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $525 · Food and Beverage: $48.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $525.00 |
| Food and Beverage | $48.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,170.90 | 2019-2023 | Calquence |
| Genzyme Corporation | $736.97 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $492.33 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $476.53 | 2019-2021 | |
| Janssen Biotech, INC. | $469.28 | 2019-2022 | |
| Daiichi Sankyo INC. | $324.92 | 2020-2021 | |
| Seagen INC. | $253.45 | 2019-2020 | |
| Astellas Pharma US INC | $241.62 | 2019-2022 | |
| Genentech USA, INC. | $239.87 | 2019-2023 | Venclexta |
| Glaxosmithkline, LLC. | $223.68 | 2019-2021 | |
| Celgene Corporation | $170.53 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $166.11 | 2019-2020 | |
| Pfizer INC. | $146.43 | 2019-2020 | |
| Tesaro, INC. | $146.09 | 2019 | |
| Advanced Accelerator Applications | $128.55 | 2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $114.84 | 2019-2020 | |
| Incyte Corporation | $78.03 | 2019-2020 | |
| Myovant Sciences INC. | $48.16 | 2021 | |
| Amgen INC. | $41.62 | 2019 | |
| Gilead Sciences, INC. | $36.01 | 2019 | |
| Kite Pharma, INC. | $33.18 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $30.00 | 2019-2020 | |
| Rigel Pharmaceuticals, INC. | $27.46 | 2021 | |
| Abbvie INC. | $23.96 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $21.40 | 2019 | |
| Dova Pharmaceuticals | $21.36 | 2020 | |
| Kyowa Kirin, INC. | $17.41 | 2020 | |
| Janssen Pharmaceuticals, INC | $17.08 | 2019 | |
| Exelixis INC. | $16.56 | 2021 | |
| Lilly USA, LLC | $16.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Calvin Rosenfeld listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.